Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
29-Dec-2025 | 1,911.3 | 1,919.1 | 1,876 | 1,889.8 | 7,851 | 8,01,44,229.8 | 28,392 |
30-Dec-2025 | 1,880 | 1,909.7 | 1,836.1 | 1,858.9 | 14,893 | 9,41,31,975.8 | 30,728 |
31-Dec-2025 | 1,849.5 | 1,932.6 | 1,849.5 | 1,928.9 | 5,756 | 4,78,53,645.2 | 14,983 |
01-Jan-2026 | 1,935 | 1,939 | 1,885 | 1,896.8 | 1,360 | 1,37,99,432.4 | 2,692 |
02-Jan-2026 | 1,885.1 | 1,950 | 1,860.1 | 1,933.3 | 6,082 | 8,97,65,428.5 | 25,249 |
05-Jan-2026 | 1,960 | 2,060 | 1,950.7 | 2,050.5 | 34,051 | 48,04,82,962.6 | 65,099 |
06-Jan-2026 | 2,048 | 2,051.6 | 2,000.1 | 2,029.8 | 9,235 | 10,44,56,943.7 | 22,119 |
07-Jan-2026 | 2,005.1 | 2,015.7 | 1,965.1 | 1,988.5 | 11,722 | 10,71,41,178.5 | 17,360 |
08-Jan-2026 | 1,980 | 1,994.8 | 1,904.7 | 1,916.1 | 4,589 | 4,90,56,448.5 | 14,760 |
09-Jan-2026 | 1,930 | 1,950.9 | 1,874.1 | 1,920.4 | 7,280 | 8,21,03,651.8 | 21,712 |
12-Jan-2026 | 1,920.4 | 1,920.4 | 1,858.1 | 1,875.1 | 7,748 | 6,19,14,401.4 | 16,813 |
13-Jan-2026 | 1,879.8 | 1,915 | 1,849.1 | 1,906.8 | 7,633 | 11,54,85,725.5 | 37,758 |
14-Jan-2026 | 1,912 | 1,988.9 | 1,875 | 1,884.5 | 23,326 | 25,26,64,565.3 | 22,761 |
16-Jan-2026 | 1,884.5 | 1,930 | 1,875.8 | 1,903.4 | 4,646 | 5,68,72,508.2 | 14,658 |
19-Jan-2026 | 1,900 | 1,924.1 | 1,886.1 | 1,910.3 | 1,573 | 1,26,54,191.8 | 3,112 |
20-Jan-2026 | 1,905 | 1,935.9 | 1,879.2 | 1,909.5 | 4,904 | 4,09,46,540.7 | 8,179 |
21-Jan-2026 | 1,875 | 1,949.9 | 1,870.1 | 1,927 | 6,483 | 4,75,08,172.1 | 11,202 |
22-Jan-2026 | 1,927 | 1,933.2 | 1,870.7 | 1,885.3 | 7,129 | 5,76,30,832.7 | 15,591 |
23-Jan-2026 | 1,885 | 1,903 | 1,791 | 1,813.4 | 6,477 | 8,65,16,978.7 | 26,497 |
Metropolis Healthcare said it plans to expand its genomic test portfolio to more than 500 advanced tests over the next two to three years
The deal includes a deferred payment of ₹1.7 crore, which will be disbursed as per the terms of the business transfer agreement, the company said in a regulatory filing.
The EBITDA margin fell to 18% in Q4 FY25 from 24.2% in Q4 FY24, reflecting a fall in operational efficiency or profitability.
The EBITDA margin was stable at 22.3% and did not change much from the year-ago period.
This is a 100% stake purchase that will be funded through 55% cash and 45% equity swap. It expects completion in 60 days, after shareholders give their nod.
Here are some of the stocks that may see significant price movement today: Tata Motors, Asian Paints, Divi’s Laboratories, etc.
Here are some of the stocks that may see significant price movement today: Titan Company, HDFC Bank, IndusInd Bank, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
